Drug intelligence / Profile preview

EV029105a

Development stage: Preclinical
Lead developer: Evec
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

EV029105a is a fully human IgG1 monoclonal antibody developed by Evec for the treatment of *Clostridium difficile* infection (CDI). The antibody is designed to target and neutralize *Clostridium difficile* toxin A (TcdA), one of the primary virulence factors responsible for the mucosal damage, inflammation, and clinical symptoms associated with CDI. By binding to toxin A, EV029105a prevents the toxin from interacting with host cell receptors, thereby mitigating its cytotoxic effects. The drug is currently in the preclinical stage of development.

Targets

TcdA-CROP (Clostridioides difficile toxin A CROP domain)

Beyond the preview

Go deeper on EV029105a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EV029105a.

Explore the full profile